GlassScriptPhysician profile
John S Mcphail
NPI 1568566719
$4,034.60
in general payments reported to CMS, 2019-2025
25 companies · $932 in 2025
The $932 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $101 · 2021: $500 · 2022: $799 · 2023: $587 · 2024: $653 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058 · Entertainment: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.12 |
| Entertainment | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,062.16 | 2019-2025 | Cequa, Xelpros |
| Sight Sciences, INC. | $555.94 | 2019-2025 | Tearcare System, Omni Surgical System |
| Biotissue Holdings INC. | $356.05 | 2022-2025 | |
| Alcon Vision LLC | $291.23 | 2019-2025 | Rocklatan, Rhopressa, Clareon |
| Mallinckrodt Hospital Products INC. | $263.36 | 2020-2025 | Acthar |
| Optos, INC. | $211.00 | 2022-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Amgen INC. | $176.09 | 2024-2025 | Tepezza |
| Abbvie INC. | $169.26 | 2023-2025 | |
| Allergan, INC. | $151.54 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $96.80 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $84.33 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $81.45 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Carl Zeiss Meditec USA, INC. | $76.92 | 2021-2022 | |
| Harrow Eye, LLC | $75.05 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $62.75 | 2023-2025 | Tyrvaya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.78 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $47.17 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $39.39 | 2019 | |
| Eyevance Pharmaceuticals LLC | $36.92 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $32.13 | 2019 | |
| Shire North American Group INC | $27.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.13 | 2019-2021 | |
| Dompe US, INC. | $21.53 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $19.70 | 2022 | |
| Spark Therapeutics, INC. | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcphail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.